In this article, we deep dive into the 5 Stocks With Remarkable Resilience. For a deeper discussion and an extended list, please see 10 Stocks With Remarkable Resilience.
Photo by Tima Miroshnichenko on Pexels
5. Sandisk Corp. (NASDAQ:SNDK)
Sandisk climbed to a fresh all-time high on Wednesday, as investor sentiment was bolstered by Morgan Stanley’s highly optimistic outlook for its stock, having upgraded its price target by 59 percent.
In intra-day trading, Sandisk Corp. (NASDAQ:SNDK) climbed to a record high of $1,861 before trimming gains to finish the session just up by 6.71 percent at $1,831.50 apiece.
In a market note, Morgan Stanley raised its price target for the memory giant to $1,750 from $1,100 previously, amid the strong demand for the NAND market, which continues to outstrip supply. In the past year alone, the company skyrocketed by as much as 4,570 percent.
“There’s no quick fix to the memory shortage,” Morgan Stanley said, adding that supply constraints are expected to persist over the next two to three years.
“We don’t think the run of strong performance is over,” it underscored.
The investment firm expects Sandisk Corp. (NASDAQ:SNDK) to grow earnings per share for this year and the next by 12 percent and 24 percent, respectively.
In other news, Sandisk Corp. (NASDAQ:SNDK) is set to participate in the Mizuho Technology Conference on Tuesday, June 9. Investors are expected to watch for the company’s business cues and updated outlook.
4. Moderna Inc. (NASDAQ:MRNA)
Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to finish at $49.06 apiece, as investors positioned portfolios ahead of its participation in a conference next week.
In a notice to investors, Moderna Inc. (NASDAQ:MRNA) said that it is set to join in the Goldman Sachs’ 47th Annual Global Healthcare Conference on Tuesday, June 9. Investors are expected to watch for the company’s updates on its pipeline progress.
Apart from Goldman Sachs, the company is also expected to hold its annual shareholders’ meeting called Science Day on June 25, 2026, where it will showcase its latest advancements in the mRNA platform science, basic research, and pipeline developments.
In other news, Moderna Inc. (NASDAQ:MRNA) presented, along with Merck, the five-year data for Intismeran Autogene in combination with Keytruda in patients with high-risk stage 3 and 4 melanoma at the recently concluded 2026 ASCO annual meeting.
According to Moderna Inc. (NASDAQ:MRNA), patients who received Intismeran Autogene in combination with Keytruda successfully reduced cancer recurrence and death risk by 49 percent, as well as its ability to spread to distant parts of the body by 59 percent.
3. POET Technologies Inc. (NASDAQ:POET)
POET Technologies saw its share prices increase by 11.29 percent on Wednesday to close at $15.38 apiece, as investors positioned their portfolios in optical companies, helped by Nvidia Corp.’s highly optimistic outlook for its counterpart.
In his onstage appearance at the Computex Week in Taipei, Taiwan, on Monday, Nvidia CEO Jensen Huang said that Marvell Technology—one of POET Technologies Inc.’s (NASDAQ:POET) counterparts—could become the “next trillion-dollar company.”
Investors were quick to position themselves in the stock, alongside key players in the industry.
Further supporting the rally were earlier announcements that POET Technologies Inc. (NASDAQ:POET) is looking to expand its wafer manufacturing capabilities by 10x by 2027 amid the strong demand for its products.
POET Technologies Inc. (NASDAQ:POET) said that it is currently in the process of expanding capacity “by roughly tenfold” in both wafer production and optical engine assembly.
“This expansion is being driven by the agreement we announced last week with Lumilens, as well as other high-volume opportunities that are near fruition. In parallel with our manufacturing scale-up, we have accelerated the hiring of engineering, technical, and management talent, bringing our total headcount to more than 115 globally. We have also expanded our Singapore lab and office footprint by nearly three times compared to last year and now have 20,000 square feet of assembly space in Malaysia,” POET Technologies Inc. (NASDAQ:POET) Chairman and CEO Suresh Venkatesan.
The company recently bagged a new supply deal with Lumilens Inc. with the potential to generate $500 million in revenues over the next five years.
It is also setting its sights on acquiring and partnering with companies that could help strengthen its engineering capabilities, broaden its product portfolio, and enhance strategic technologies and components.
2. Navitas Semiconductor Corp. (NASDAQ:NVTS)
Navitas Semiconductor climbed to a new all-time high on Wednesday, after its technology was showcased by Nvidia Corp. at the Computex 2026 in Taipei, Taiwan.
In intra-day trading, the stock climbed to its highest price of $34.16 at intra-day trading before paring gains to finish the session just up by 19.14 percent at $30.81 apiece.
In a statement, Navitas Semiconductor Corp. (NASDAQ:NVTS) said that Nvidia featured its 800 V-to-6 V DC-DC power delivery board (PDB) in its AI Factory MGX Ecosystem Showcase. Thanks to Navitas GaNFast technology, the PDB features the latest DFN8×8 dual-cooled package, aiming a peak efficiency of 97.5 percent and switching frequency of 1 MHz, among others.
It is also around 20 percent thinner than a mobile phone, while its ultra-low profile allows for extremely close integration with the GPU board, maximizing transient performance and enhancing power distribution efficiency.
Through its comprehensive portfolio of GaN and SiC technologies, Navitas Semiconductor Corp. (NASDAQ:NVTS) said that it continues to collaborate closely with Nvidia within the MGX ecosystem, helping enable open, modular AI infrastructure architectures and accelerating the industry’s transition toward next-generation AI factories.
“As AI workloads continue to scale and drive unprecedented demand for compute, power delivery has become one of the most critical challenges in enabling next-generation gigawatt AI factories,” Navitas Semiconductor Corp. (NASDAQ:NVTS) President and CEO Chris Allexandre said.
“Through our collaboration with NVIDIA within the MGX ecosystem, Navitas is delivering GaN and SiC power technologies that enable megawatt-scale AI server racks with higher power density, a smaller system footprint, and improved thermal performance, helping accelerate the transition to more efficient and scalable AI infrastructure,” he added.
1. Abivax SA (NASDAQ:ABVX)
Abivax soared by 24.34 percent on Wednesday to close at $90.15 apiece, as investors resorted to bargain-hunting to take advantage of its low price following its steep drop in the previous trading day, dragged by concerns about its cancer therapy candidate.
Earlier in the week, Abivax SA (NASDAQ:ABVX) announced strong clinical trial results from the third phase study evaluating Obefazimod in patients with moderate to severe active ulcerative colitis.
While the drug achieved its primary endpoint of demonstrating clinically meaningful efficacy and a placebo-adjusted remission rate of about 40 percent, the results were overshadowed by concerns about other cancer cases taking higher doses.
″[The] cancer signal complicates matters,” said investment firm Jefferies in its market note.
“Even if unrelated noise, we think the overhang will be real, especially considering the absence of other value-inflecting data events over the next [year].”
Following the results, Jefferies downgraded Abivax SA (NASDAQ:ABVX) to hold from buy, as well as its price target, by 43.75 percent to $90 from $160 previously.
Apart from Jefferies, Abivax SA (NASDAQ:ABVX) also earned a 22-percent lower price target from Wolfe Research, to $136 from $176 previously, but maintained its outperform rating for its stock.
Wolfe said that the coverage was based on various factors, including background rates higher than normal, an older patient population, and the lack of a data safety monitoring board and nonclinical genotoxicity signals.
However, the listed firm is set to provide a safety and efficacy update later this month, which Wolfe said may reinforce optimism anew among investors on expectations that the biopharmaceutical firm would devise a communication strategy to address concerns.
While we acknowledge the potential of ABVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABVX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
